Advertisement
New Zealand markets close in 4 hours 8 minutes

  • NZX 50

    11,848.36
    +45.08 (+0.38%)
     

  • NZD/USD

    0.5944
    +0.0010 (+0.16%)
     

  • NZD/EUR

    0.5547
    +0.0006 (+0.11%)
     

  • ALL ORDS

    7,974.70
    +36.80 (+0.46%)
     

  • ASX 200

    7,720.40
    +36.90 (+0.48%)
     

  • OIL

    83.44
    +0.08 (+0.10%)
     

  • GOLD

    2,335.00
    -7.10 (-0.30%)
     

  • NASDAQ

    17,471.47
    +260.59 (+1.51%)
     

  • FTSE

    8,044.81
    +20.94 (+0.26%)
     

  • Dow Jones

    38,503.69
    +263.71 (+0.69%)
     

  • DAX

    18,137.65
    +276.85 (+1.55%)
     

  • Hang Seng

    16,828.93
    +317.24 (+1.92%)
     

  • NIKKEI 225

    38,293.43
    +741.27 (+1.97%)
     

  • NZD/JPY

    91.9050
    +0.1390 (+0.15%)
     

Intercept to Announce Second Quarter 2022 Financial Results on August 3, 2022

Intercept Pharmaceuticals, Inc.
·1-min read
Intercept Pharmaceuticals, Inc.
Intercept Pharmaceuticals, Inc.

MORRISTOWN, N.J., July 27, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its second quarter 2022 financial results prior to market open on Wednesday, August 3, 2022. The announcement will be followed by a conference call and audio webcast hosted by Intercept management at 8:30 a.m. ET to discuss the results.

Participants can access the conference call live via webcast which will be available on the investor page of our website at http://ir.interceptpharma.com. Participants who wish to ask a question may register here to receive dial-in numbers and a unique pin to join the call. While not required, it is recommended you join 10 minutes prior to the event's start. A replay of the call will be available on our website shortly following the completion of the call and will be available for one year.

About Intercept 
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). For more information, please visit www.interceptpharma.com or connect with the company on Twitter and LinkedIn.

ADVERTISEMENT

Contact 
For more information about Intercept, please contact:

For investors: 
Nareg Sagherian, Executive Director, Global Investor Relations 
investors@interceptpharma.com

For media: 
Karen Preble, Executive Director, Global Corporate Communications 
media@interceptpharma.com